News & Updates

Neoadjuvant pembrolizumab plus chemotherapy improves event-free survival (EFS) in high-risk, early-stage triple-negative breast cancer (TNBC) patients with residual cancer burden (RCB), suggests a study.

Dropping aspirin for ticagrelor monotherapy 1 month after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) is as good as dual antiplatelet therapy (DAPT) in the ULTIMATE-DAPT* trial presented at ACC.24.

Dual therapy with vonoprazan and amoxicillin (VA-dual) for 10 days results in a 90.8-percent eradication rate of Helicobacter pylori (H pylori) and fewer adverse events (AEs) compared with the standard 14-day bismuth-based quadruple therapy (B-quadruple), a study has shown.

Olanzapine appears to be just as effective as fosaprepitant, a neurokinin-1 receptor antagonist (NK1-RA), in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic malignancies who were receiving carboplatin/paclitaxel chemotherapy every 3 weeks, a prospective study presented at SGO 2024 suggests. However, the former trumps the latter in terms of cost effectiveness.

Soft topical steroid application and standard steroid treatment demonstrate similar efficacy and safety in patients who underwent cataract surgery, reports a study.